Skip to search formSkip to main contentSkip to account menu

Posicor

Known as: Roche Brand of Mibefradil Dihydrochloride 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

MibefradilQuinazolines
Mibefradil Dihydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
A POTENT INHIBITOR OF BOTH P-GLYCOPROTEIN AND CYP 3 A IN VITRO
Mibefradil, a calcium Tand L-channel blocker developed for use in hypertension, was recently removed from the market after… 
1998
1998
The withdrawal of mibefradil (Posicor)
1998
1998
The withdrawal of mibefradil (Posicor)
1998
1998
Product Focus: Posicor®t (mibefradil)
Posicor has recently been licenced for the treatment of hypertension and angina pectoris. Helen Reilly looks at its uses in the… 
1998
1998
Mibefradil (Posicor) induced sinus arrest.
1998
1998
Posicor withdrawn voluntarily from market by Roche
1997
1997
Metabolism of the calcium antagonist, mibefradil (POSICOR, Ro 40-5967). Part III. Comparative pharmacokinetics of mibefradil and its major metabolites in rat, marmoset, cynomolgus monkey and man.
1. The metabolism of mibefradil has been examined in rat, marmoset, cynomolgus monkey and man after single and multiple oral… 
1997
1997
Asymmetric Hydrogenation vs. Resolution in the Synthesis of POSICOR®, a New Type of Calcium Antagonist
The pilot-plant-scale synthesis of (S)-2-(4-fluorophenyl)-3-methylbutanoic acid by asymmetric hydrogenation of 2-(4-fluorophenyl… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)